Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 29;135(19):e193107.
doi: 10.1172/JCI193107. eCollection 2025 Oct 1.

Elesclomol-copper therapy improves neurodevelopment in two children with Menkes disease

Elena Godoy-Molina  1   2 , Natalia L Serrano  3 , Aquilina Jiménez-González  4 , Miquel Villaronga  5 , Rosa M Marqués Pérez-Bryan  6 , Rubén Varela-Fernández  7 , Stephanie Lotz-Esquivel  3 , Alba Hevia Tuñón  4 , Prachi P Trivedi  8 , Nina Horn  9 , Joseph F Standing  10   11 , Víctor Mangas-Sanjuan  12   13 , Mercè Capdevila  14 , Aurora Mateos  15   16 , Denis Broun  15 , Svetlana Lutsenko  17 , Ines Medina-Rivera  18 , Rafael Artuch  19   20 , Cristina Jou  21 , Mònica Roldán  22 , Pedro Arango-Sancho  23 , Mónica Saez-Villafañe  7 , Juan J Ortiz-de-Urbina  7 , Angela Pieras-López  5 , Marta Duero  5 , Rosa Farré  5 , Jordi Pijuan  3   20 , Janet Hoenicka  3   20 , James C Sacchettini  8 , Michael J Petris  24 , Vishal M Gohil  8 , Francesc Palau  3   20   25   26
Affiliations

Elesclomol-copper therapy improves neurodevelopment in two children with Menkes disease

Elena Godoy-Molina et al. J Clin Invest. .
No abstract available

Keywords: Clinical Research; Genetic diseases; Genetics; Neurodegeneration; Neuroscience; Therapeutics.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The conflict-of-interest statement appears in the supplemental materials.

Figures

Figure 1
Figure 1. Evolution of neurodevelopmental milestones in NP#1 and NP#2 following the treatment with ES-Cu.
(A and B) Measurements for each neurological domain were taken using the Bayley-III scale. (A) For NP#1, evaluations occurred every 2 months during the first 20 months (20–40 months of age), while (B) NP#2 was assessed at 4 intervals. (C and D) Comparison of Bayley-III domain scores at age 20 months between (C) NP#1 and (D) NP#2. (E) Comparison of gross motor milestones acquisition between NP#1 and NP#2. LoF, loss of function.
See this image and copyright information in PMC

References

    1. Sarkar B, et al. Copper-histidine therapy for Menkes disease. J Pediatr. 1993;123(5):828–830. doi: 10.1016/S0022-3476(05)80870-4. - DOI - PubMed
    1. Kaler SG, et al. Neonatal diagnosis and treatment of Menkes disease. N Engl J Med. 2008;358(6):605–614. doi: 10.1056/NEJMoa070613. - DOI - PMC - PubMed
    1. Guthrie LM, et al. Elesclomol alleviates Menkes pathology and mortality by escorting Cu to cuproenzymes in mice. Science. 2020;368(6491):620–625. doi: 10.1126/science.aaz8899. - DOI - PMC - PubMed
    1. Zulkifli M, et al. Elesclomol rescues mitochondrial copper deficiency in disease models without triggering cuproptosis. J Pharmacol Exp Ther. 2025;392(2):100048. doi: 10.1016/j.jpet.2024.100048. - DOI - PubMed